[{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Melatonin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Cleveland Clinic \/ Not Applicable"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Cytocom","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Merger","leadProduct":"CYTO-200","moa":"","graph1":"Gastroenterology","graph2":"Phase II\/ Phase III","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Cleveland BioLabs","highestDevelopmentStatusID":"9","companyTruncated":"Cleveland Clinic \/ Cleveland BioLabs"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Anixa Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Anixa Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"Cleveland Clinic \/ Anixa Biosciences"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"AriBio","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Methylbenzylamine","moa":"PDE5","graph1":"Neurology","graph2":"Phase II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cleveland Clinic \/ Cleveland Clinic Genomic Medicine Institute","highestDevelopmentStatusID":"8","companyTruncated":"Cleveland Clinic \/ Cleveland Clinic Genomic Medicine Institute"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Anixa Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Ovarian Cancer Vaccine","moa":"ED-AMHR2","graph1":"Oncology","graph2":"Preclinical","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Cleveland Clinic","highestDevelopmentStatusID":"4","companyTruncated":"Cleveland Clinic \/ Cleveland Clinic"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Synaptogenix","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Bryostatin-1","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Synaptogenix","highestDevelopmentStatusID":"4","companyTruncated":"Cleveland Clinic \/ Synaptogenix"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Anixa Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Partnership","leadProduct":"Alpha-lactalbumin-based Vaccine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Cleveland Clinic","highestDevelopmentStatusID":"6","companyTruncated":"Cleveland Clinic \/ Cleveland Clinic"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"TFF Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Cleveland Clinic","highestDevelopmentStatusID":"14","companyTruncated":"Cleveland Clinic \/ Cleveland Clinic"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"NeuroTherapia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"NTRX-07","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cleveland Clinic","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cleveland Clinic \/ Cleveland Clinic","highestDevelopmentStatusID":"14","companyTruncated":"Cleveland Clinic \/ Cleveland Clinic"}]

Find Clinical Drug Pipeline Developments & Deals by Cleveland Clinic

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : NeuroTherapia will use this funding primarily for the continued clinical development of NTRX-07, an orally available cannabinoid receptor agonist, for the treatment of Alzheimer's disease

                          Brand Name : NTRX-07

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 06, 2024

                          Lead Product(s) : NTRX-07

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Recipient : NeuroTherapia

                          Deal Size : $12.3 million

                          Deal Type : Series B Financing

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : TFF collaborates with Cleveland to advance multiple multivalent universal influenza vaccines, which are being evaluated in early-stage clinical trials to protect against seasonal & pandemic viruses.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 20, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Recipient : TFF Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the expanded partnership, companies will co-develop vaccines for cancers. Cleveland Clinic is conducting a Phase 1 trial for triple-negative breast cancer.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 08, 2024

                          Lead Product(s) : Alpha-lactalbumin-based Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Anixa Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The agreement aims to conduct a phase 1 trial of Bryostatin-1, a small molecule that works by activating protein kinase C, in multiple sclerosis (MS).

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 19, 2023

                          Lead Product(s) : Bryostatin-1

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Synaptogenix

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : By developing ovarian cancer vaccine that target alpha-lactalbumin and AMHR2-ED, immune system can destroy breast cancer cells and ovarian cancer cells, respectively, as they arise and ultimately prevent tumors from forming.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 12, 2022

                          Lead Product(s) : Ovarian Cancer Vaccine

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Anixa Biosciences

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Positive Phase II trial reported for AR1001, the results confirmed the possibility of developing a unique oral disease-modifying treatment for AD that improves cognitive function. The Company will complete Phase III clinical trials of AR1001 within the n...

                          Brand Name : AR1001

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 20, 2021

                          Lead Product(s) : Methylbenzylamine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Recipient : AriBio

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The investigational vaccine targets a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues but is present in the majority of triple-negative breast cancers.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          October 26, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Anixa Biosciences

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Combined public entity to develop and commercialize next-generation immune therapies like CYTO-200, that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions.

                          Brand Name : CYTO-200

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 17, 2021

                          Lead Product(s) : CYTO-200

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II/ Phase III

                          Recipient : Cytocom

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Results from a new Cleveland Clinic-led study suggest that melatonin, a hormone that regulates the sleep-wake cycle and is commonly used as an over-the-counter sleep aid, may be a viable treatment option for COVID-19.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 13, 2020

                          Lead Product(s) : Melatonin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank